Access to continued treatment with dabrafenib and/or trametinib for eligible patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study provides ongoing access to patients who have been receiving treatment with dabrafenib and/or trametinib in previous Novartis or former GSK-sponsored studies. It aims to allow patients who have met the primary objectives of those studies and are deemed by investigators to benefit from continued treatment to remain on these therapies. The study focuses on patients with conditions such as melanoma, non-small cell lung cancer, and other solid tumors. It is designed to ensure that patients who have shown positive responses can continue their treatment without interruption.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
* In the opinion of the Investigator would benefit from continued treatment.

Exclusion Criteria:

* Patient has been previously permanently discontinued from study treatment in the parent protocol.
* Patient's indication is commercially available and reimbursed in the local country.
* Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.

Where it's running

• Novartis Investigative Site
  Toronto, Ontario, Canada Recruiting
• Novartis Investigative Site
  Villejuif, France Recruiting
• Novartis Investigative Site
  Barcelona, Spain Recruiting
• Novartis Investigative Site
  Madrid, Spain Recruiting
• Novartis Investigative Site
  Madrid, Spain Recruiting
• Honor Health Research Institute
  Scottsdale, Arizona, United States Active not recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: 1-888-669-6682

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oncolytic virus treatment combined with nivolumab for advanced solid tumors

  This study is testing a new virus treatment combined with an existing cancer drug to see if it can help people with advanced solid tumors, like lung cancer, whose cancer has not improved with previous treatments.

  Recruiting Phase 1 Memgen, Inc. · Tampa, Florida and 1 other locations · NCT05076760

• Evaluating the safety and effectiveness of ST-067 in treating various solid tumors

  This study is testing a new treatment called ST-067 to see if it can help people with tough-to-treat solid tumors feel better and improve their health.

  Recruiting at 6 sites Phase 1/2 Simcha IL-18, Inc. · Scottsdale, Arizona and 5 other locations · NCT04787042

• Testing a new treatment for advanced solid tumors with pembrolizumab

  This study is testing a new treatment using INBRX-106 alone and with pembrolizumab to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1/2 Inhibrx Biosciences, Inc · Duarte, California and 59 other locations · NCT04198766

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• IBI3028 in advanced solid tumors

  This phase 1 study tests IBI3028 in adults with unresectable or metastatic solid tumors to see if it is safe and how patients tolerate it.

  Recruiting Phase 1 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tianjin, Tianjin Municipality · NCT07589205

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.